HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomononuclear cell recruitment

被引:41
作者
Arese, M
Ferrandi, C
Primo, L
Camussi, G
Bussolino, F
机构
[1] Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy
[2] Univ Turin, Sch Med, Dept Genet Biol & Biochem, I-10060 Turin, Italy
[3] Univ Turin, Sch Med, Dept Med & Surg Sci, I-10060 Turin, Italy
关键词
D O I
10.4049/jimmunol.166.2.1380
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV-1 Tat protein released by infected cells is a chemotactic molecule for leukocytes and induces a proinflammatory program in endothelial cells (EC) by activating vascular endothelial growth factor (VEGF) receptors expressed on both cell types. Its potential role in causing vascular permeability and leukocyte recruitment was studied in vivo following its s.c. injection in mice. Tat caused a dose-dependent early (15 min) and late (6 h) wave of permeability that were inhibited by a neutralizing Ab anti-VEGF receptor type 2. Tissue infiltration of lymphomononuclear cells, mainly monocytes (76%), was evident at 6 h and persisted up to 24 h. WEB2170, a platelet activating factor (PAF) receptor antagonist, reduced the early leakage by 70-80%, but only slightly inhibited the late wave and cell recruitment. In vitro, Tat induced a dose-dependent flux of albumin through the EC monolayer that was inhibited by Ab anti-vascular VEGF receptor type 2 and WEB2170, and PAF synthesis in EC that was blocked by the Ab anti-VEGF receptor type 2. Lastly, an anti-monocyte chemotactic peptide-1 (MCP-1) Ab significantly reduced the lymphomononuclear infiltration elicited by Tat. In vitro, Tat induced a dose-dependent production of MCP-1 by EC after a 24-h stimulation. These results highlighted the role of PAF and MCP-1 as secondary mediators in the onset of lymphomononuclear cell recruitment in tissues triggered by Tat.
引用
收藏
页码:1380 / 1388
页数:9
相关论文
共 76 条
  • [1] Albini A, 1996, ONCOGENE, V12, P289
  • [2] HIV-1 Tat protein mimicry of chemokines
    Albini, A
    Ferrini, S
    Benelli, R
    Sforzini, S
    Giunciuglio, D
    Aluigi, MG
    Proudfoot, AEI
    Alouani, S
    Wells, TNC
    Mariani, G
    Rabin, RL
    Farber, JM
    Noonan, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) : 13153 - 13158
  • [3] The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
    Albini, A
    Soldi, R
    Giunciuglio, D
    Giraudo, E
    Benelli, R
    Primo, L
    Noonan, D
    Salio, M
    Camussi, G
    Rockl, W
    Bussolino, F
    [J]. NATURE MEDICINE, 1996, 2 (12) : 1371 - 1375
  • [4] Identification of a novel domain of HIV Tat involved in monocyte chemotaxis
    Albini, A
    Benelli, R
    Giunciuglio, D
    Cai, T
    Mariani, G
    Ferrini, S
    Noonan, DM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) : 15895 - 15900
  • [5] Barillari G, 1999, BLOOD, V94, P663
  • [6] The human immunodeficiency virus type 1 regulatory protein Tat inhibits interferon-induced iNos activity in a murine macrophage cell line
    Barton, CH
    Biggs, TE
    Mee, TR
    Mann, DA
    [J]. JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 1643 - 1647
  • [7] Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent
    Bernatchez, PN
    Soker, S
    Sirois, MG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) : 31047 - 31054
  • [8] NEURONAL EXPRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENV PROTEINS IN TRANSGENIC MICE - DISTRIBUTION IN THE CENTRAL-NERVOUS-SYSTEM AND PATHOLOGICAL ALTERATIONS
    BERRADA, F
    MA, DM
    MICHAUD, J
    DOUCET, G
    GIROUX, L
    KESSOUSELBAZ, A
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (11) : 6770 - 6778
  • [9] THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT PROTEIN TRANSACTIVATES TUMOR-NECROSIS-FACTOR BETA-GENE EXPRESSION THROUGH A TAR-LIKE STRUCTURE
    BUONAGURO, L
    BUONAGURO, FM
    GIRALDO, G
    ENSOLI, B
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (04) : 2677 - 2682
  • [10] BUSSOLINO F, 1991, J IMMUNOL, V147, P2122